Contrave and Zepbound are two U.S. Food and Drug Administration (FDA)-approved medications for weight loss when combined with diet and exercise. But each medication works in different ways in the body ...

GLP-1 microdosing is when people take smaller doses of GLP-1 drugs than are typically prescribed or FDA-recommended, often ...

The new GLP-1 $50 copay significantly lowers that barrier for eligible Medicare beneficiaries. That change can massively ...

On Friday, the state’s Medicaid administrator, MassHealth, ends coverage of GLP-1s and other medications when they’re ...

Roughly one in eight American adults is now taking a GLP-1 drug like Ozempic, Wegovy or Zepbound. The class traces back to a hormone isolated from Gila monster venom by a Bronx doctor who paid a ...

Medicare began covering certain GLP-1 weight loss drugs on July 1, 2026, giving millions of eligible beneficiaries access to ...

GoodRx reports that Medicare's new GLP-1 Bridge program allows eligible Part D enrollees to access weight-loss medications ...

Millions of Medicare beneficiaries will gain access to obesity drugs for the first time starting Wednesday under CMS’ ...

The buzz around weight-loss drugs has never been louder or more exciting, especially when it comes to a brand new option ...

The federal government has launched a new program to make GLP-1 weight loss drugs more affordable for older Americans.

CMS says the 18-month demonstration will expand access to select weight-loss drugs while the agency gathers data on uptake, outcomes and program operations.

Millions of Americans are expected ⁠to ⁠gain coverage for GLP-1 drugs for weight loss ⁠under a new U.S. pilot launching on ...